echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > NEJM: 177Lu-PSMA-617 targeted radiotherapy for the treatment of metastatic castration-resistant prostate cancer

    NEJM: 177Lu-PSMA-617 targeted radiotherapy for the treatment of metastatic castration-resistant prostate cancer

    • Last Update: 2021-09-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Castration-resistant prostate cancer (CRPC) patients still progress after the initial continuous androgen deprivation treatment.


    Recently, researchers evaluated the therapeutic effect of 177Lu-PSMA-617 on mCRPC patients


    This study is an international, public, phase III trial.


    immunity

    A total of 831 patients participated in the study, and the baseline characteristics of the patients were similar


    Compared with standard care, in the 177Lu-PSMA-617 group, imaging-based progression-free survival (median progression-free survival: 8.


    Differences in progression-free survival and overall survival between groups

    Differences in progression-free survival and overall survival between groups

    For patients with advanced PSMA-positive metastatic castration-resistant prostate cancer, 177Lu-PSMA-617 targeted radiotherapy can significantly improve the patient's progression-free survival rate and overall survival rate


    For patients with advanced PSMA-positive metastatic castration-resistant prostate cancer, 177Lu-PSMA-617 targeted radiotherapy can significantly improve the patient’s progression-free survival rate and overall survival rate.


    Original source:

    Oliver Sartor et al.


    Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.